NA
CRSP icon

Neuburgh Advisers’s CRISPR Therapeutics CRSP Stock Holding History

Neuburgh Advisers’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,360
Closed -$62K – 885
2018
Q1 		$62K Buy
+1,360
New +$56.1K ﹤0.01% 838

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Neuburgh Advisers's CRSP Position: Q2 2018 in Review

Neuburgh Advisers sold out of CRISPR Therapeutics (CRSP) in Q2 2018, closing a stake of 1,360 shares — an estimated $62K sold.

Neuburgh Advisers first reported a position in CRSP in Q1 2018 and held it in 1 quarter. The position peaked at $62K in Q1 2018. 174 funds tracked by Wall St. Rank hold CRSP as of Q2 2018.

  • Neuburgh Advisers reported no remaining CRISPR Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Neuburgh Advisers sold 1,360 CRISPR Therapeutics shares in Q2 2018, an estimated $62K.
  • Neuburgh Advisers first reported a position in CRISPR Therapeutics in Q1 2018 and held it in 1 quarter.
  • Neuburgh Advisers's CRISPR Therapeutics position peaked at $62K in Q1 2018.
  • 174 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2018.

Based on Neuburgh Advisers's 13F filing for Q2 2018, filed 10 Aug 2018.